Resonant Clinical Solutions acquired France-based Creapharm Bioservices from Myonex, expanding its European biorepository capabilities and specialized support for complex clinical programs, including cell and gene therapies. Based in Bailly-Romainvilliers, Creapharm provides biobanking and cryogenic storage for biotherapeutics, Advanced Therapy Medicinal Products (ATMPs), and biological samples, including liquid- or vapor-phase nitrogen storage at temperatures as low as -196 °C. Its capabilities also include mechanical deep-freeze and refrigerated storage, GMP-compliant sample storage, GDP-compliant quality-control sample retention, traceability from controlled room temperature through cryogenic conditions, and handling of Class 1 and Class 2 genetically modified organisms. Creapharm is now part of Resonant’s biorepository business. Resonant cited growing specialization in clinical pipelines, while an IQVIA study published in August 2025 found that non-small-molecule medicines represented 46% of newly initiated Phase I to III clinical trials in 2024, up from 38% five years earlier. Financial terms were not disclosed.